14 results on '"Forman, Stephen J"'
Search Results
2. Body composition and late‐occurring chronic health conditions after autologous stem cell transplantation for lymphoma.
- Author
-
Giri, Smith, Harmon, Christian, Landier, Wendy, Chen, Yanjun, Wu, Jessica, Hageman, Lindsey, Balas, Nora, Francisco, Liton, Bosworth, Alysia, Weisdorf, Daniel J., Forman, Stephen J., Armenian, Saro H., Williams, Grant R., and Bhatia, Smita
- Subjects
BODY composition ,STEM cell transplantation ,CHRONIC diseases ,ADIPOSE tissues ,MUSCLE mass ,ADIPOSE tissue diseases ,VISCERAL pain - Abstract
Background: Autologous peripheral blood stem cell transplantation (aPBSCT) is the standard of care for adults with relapsed lymphoma, yet recipients remain at risk of developing chronic health conditions (CHCs). It was hypothesized that body composition measurements of skeletal muscle and fat are associated with late‐onset CHCs and nonrelapse mortality after aPBSCT. Methods: Leveraging the Blood or Marrow Transplant Survivor Study, we examined association between pre‐aPBSCT body composition and new‐onset grade 3–5 CHCs among 187 adults with lymphoma treated with aPBSCT (2011–2014) surviving ≥2 years after aPBSCT. Using computed tomography scans at the L3 level, skeletal muscle mass (skeletal muscle area and skeletal muscle density [SMD]) and body fat (subcutaneous adipose tissue and visceral adipose tissue) were measured and quantified as sex‐specific z‐scores. Competing risk models were built to study the impact of body composition on incident grade 3 through 5 CHCs and nonrelapse mortality (NRM) adjusting for confounders. Results: The study cohort had a median age at aPBSCT of 57 years with 63% males, 77% non‐Hispanic Whites and 81% with non‐Hodgkin lymphoma. The 5‐year cumulative incidence of grade 3 through 5 CHCs was 47% (95% Confidence Interval, CI, 38%–56%). Each SD increase in SMD was associated with 30% reduced risk of grade 3 through 5 CHCs (95% CI, 0.50–0.96). The 10‐year cumulative incidence of NRM was 16% (95% CI, 10–22). No body composition measure was associated with NRM. Conclusions: The association between SMD and grade 3 through 5 CHCs following aPBSCT could inform development of prognostic models to identify adults with lymphoma at greatest risk of morbidity following aPBSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia.
- Author
-
Othman, Tamer, Koller, Paul, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Tinajero, Jose, Ali, Haris, Cai, Ji‐Lian, Mei, Matthew, Aribi, Ahmed, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, and Aldoss, Ibrahim
- Subjects
INFORMED consent (Medical law) ,REGULATORY T cells ,CYTOKINE release syndrome ,CHILD patients ,T-cell exhaustion - Abstract
This article examines the use of tyrosine kinase inhibitor (TKI) therapy as a maintenance treatment after chimeric antigen receptor (CAR) T-cell therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who cannot undergo allogeneic hematopoietic cell transplantation (alloHCT). The study presents a case series of seven patients who received CAR-T cells for relapsed/refractory Ph+ ALL and subsequently received TKI maintenance. The article discusses the patients' characteristics and outcomes, emphasizing the need for further research and data on this approach. The study suggests that TKI maintenance therapy after CAR-T may be beneficial, particularly in patients who achieve complete molecular remission (CMR) and have no evidence of minimal residual disease (MRD). The authors recommend larger prospective trials to confirm the effectiveness and safety of TKI maintenance therapy post-CAR-T, and to explore its potential application to other subtypes of ALL. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
4. Health care utilization by long‐term survivors of blood or marrow transplantation—A Bone Marrow Transplant Survivor Study report.
- Author
-
Oliver, Marian M., Meng, Qingrui, Hageman, Lindsey, Landier, Wendy, Balas, Nora, Ross, Elizabeth, Francisco, Liton, Bosworth, Alysia, Te, Hok Sreng, Wong, F. Lennie, Bhatia, Ravi, Forman, Stephen J., Armenian, Saro H., Weisdorf, Daniel J., and Bhatia, Smita
- Subjects
MEDICAL care use ,LONG-term health care ,BONE marrow ,PHYSICIAN services utilization ,UTILIZATION review (Medical care) ,MEDICAL records - Abstract
Background: Blood or marrow transplantation (BMT) survivors carry a high burden of morbidity, yet health care utilization by this vulnerable population remains understudied. Patterns and predictors of various domains of health care utilization in long‐term BMT survivors were evaluated. Methods: Study participants were drawn from the Bone Marrow Transplant Survivor Study (BMTSS). Patients transplanted between 1974 and 2014 at one of three transplant centers who had survived ≥2 years after BMT and were aged ≥18 years at the time of the study were included. A BMTSS survey served as the source of data for health care utilization, sociodemographics, and chronic health conditions. Domains of health care utilization in the 2 years preceding study participation included routine checkups, BMT‐related visits, transplant/cancer center visits, emergency room (ER) visits, hospitalizations, and high health care utilization (≥7 physician visits during the 2 years before the study). Clinical characteristics and therapeutic exposures were abstracted from medical records. Results: In this cohort of 3342 BMT survivors (52% allogeneic), the prevalence of health care utilization declined over time since BMT for both allogeneic and autologous BMT survivors, such that among those who had survived ≥20 years, only 49%–53% had undergone routine checkups, 37%–38% reported BMT‐related visits, and 28%–29% reported transplant/cancer center visits. The presence of severe/life‐threatening conditions and chronic graft‐vs‐host disease increased the odds of health care utilization across all domains. Lower education, lack of insurance, and Hispanic ethnicity were associated with a lower prevalence of routine checkups and/or transplant/cancer center visits. Lower income increased the odds of ER visits but reduced the odds of hospitalizations or high health care utilization. Conclusions: This study identified vulnerable populations of long‐term BMT survivors who would benefit from specialized risk‐based anticipatory care to reduce high health care utilization, ER visits, and hospitalizations. Health care utilization (including routine medical checkups) declines with increasing time since blood or marrow transplantation, except among survivors with severe/life‐threatening chronic health conditions as well as those with chronic graft‐vs‐host disease. Lower education and lack of insurance are associated with lower health care utilization. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma.
- Author
-
Ong, Shin Yeu, Pak, Stacy, Mei, Matthew, Wang, Yan, Popplewell, Leslie, Baird, John H., Herrera, Alex F., Shouse, Geoffrey, Nikolaenko, Liana, Zain, Jasmine, Godfrey, James, Htut, Myo, Aribi, Ahmed, Spielberger, Ricardo, Mansour, Joshua, Forman, Stephen J., Palmer, Joycelynne, and Budde, Lihua E.
- Published
- 2023
- Full Text
- View/download PDF
6. Potentially inappropriate medications in geriatric blood or marrow transplantation (BMT) survivors: A BMT Survivor Study report.
- Author
-
Sanchez‐Luege, Sebastian, Landier, Wendy, Dai, Chen, Hageman, Lindsey, Ross, Elizabeth S., Balas, Nora A., Bosworth, Alysia, Te, Hok Sreng, Wu, Jessica, Francisco, Liton, Wong, F. Lennie, Forman, Stephen J., Armenian, Saro H., Weisdorf, Daniel J., and Bhatia, Smita
- Subjects
INAPPROPRIATE prescribing (Medicine) ,GRAFT versus host disease ,BONE marrow ,LOGISTIC regression analysis ,OLDER people - Abstract
Background: Blood or marrow transplantation (BMT) is increasingly offered to older individuals with hematologic malignancies. The high prevalence of chronic health conditions in such individuals necessitates use of multiple medications. Beers Criteria represent a list of potentially inappropriate medications (PIMs) shown to increase the risk of health problems in the elderly. We sought to determine the prevalence and predictors of PIM use in older BMT survivors and identify associations with health problems. Methods: Study participants were drawn from the BMT Survivor Study, a cohort study of patients transplanted at three US transplant centers between 1974 and 2014 and surviving ≥2 years. For this report, the survivors were aged ≥65 years. Siblings served as a comparison group. Participants self‐reported sociodemographics, chronic health conditions, and medication use. Logistic regression analyses identified predictors of PIM use and associations with health problems. Results: Overall, PIM use was comparable between BMT survivors (49.4%) and siblings (49.3%) (odds ratio [OR] = 0.9; 95% CI, 0.7–1.2); however, BMT survivors were more likely to use >1 PIM (17.4% vs. 12.4%; OR = 1.5; 95% CI, 1.01–2.4) and central nervous system–related PIMs (8.3% vs. 4.3%; OR = 2.18; 95% CI, 1.17–4.09). Predictors of PIM use included presence of severe/life‐threatening chronic health conditions (OR = 1.5; 95% CI, 1.1–2.0), and chronic graft versus host disease (OR = 1.7; 95% CI, 1.1–2.7). Survivors taking >1 PIM reported more issues with vertigo (OR = 2.3; 95% CI, 1.1–4.7), balance (OR = 2.6; 95% CI, 1.7–4.1), faintness/dizziness (OR = 2.8; 95% CI, 1.8–4.6), and personal care (OR = 4.5; 95% CI, 1.4–14.8). Conclusions: This study shows the health problems associated with PIM use and identifies vulnerable populations at higher risk for PIM use, providing evidence for caution in using PIMs in high‐risk populations. Older blood or marrow transplantation survivors were more likely to use multiple potentially inappropriate medications than a sibling comparison group. Survivors with multimorbidity and/or chronic graft versus host disease were more likely to use these medications; survivors taking multiple potentially inappropriate medications reported several health problems. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Adoptive transfer of functional SARS‐COV‐2‐specific immunity from donor graft to hematopoietic stem cell transplant recipients.
- Author
-
La Rosa, Corinna, Chiuppesi, Flavia, Park, Yoonsuh, Gendzekhadze, Ketevan, Zhou, Qiao, Faircloth, Katelyn, Kaltcheva, Teodora, Johnson, Daisy, Ortega Francisco, Sandra, Amanam, Idoroenyi, Otoukesh, Salman, Pullarkat, Vinod A., Nakamura, Ryotaro, Diamond, Don J., Forman, Stephen J., and Al Malki, Monzr M.
- Published
- 2022
- Full Text
- View/download PDF
8. The feasibility of additional CD19‐targeted cellular therapy in relapsed/refractory B‐ALL with re‐emergence of CD19 antigen after prior CD19‐negative relapse.
- Author
-
Agrawal, Vaibhav, Salhotra, Amandeep, Song, Joo, Gu, Zhaohui, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, and Aldoss, Ibrahim
- Published
- 2023
- Full Text
- View/download PDF
9. Peripheral blood parameter abnormalities precede therapy‐related myeloid neoplasms after autologous transplantation for lymphoma.
- Author
-
Bachiashvili, Kimo, Francisco, Liton, Chen, Yanjun, Bosworth, Alysia, Forman, Stephen J., Bhatia, Ravi, and Bhatia, Smita
- Subjects
AUTOTRANSPLANTATION ,LEUCOCYTES ,TOTAL body irradiation ,STEM cell transplantation ,HODGKIN'S disease - Abstract
Background: Therapy‐related myeloid neoplasms (t‐MN) are a leading cause of nonrelapse mortality after autologous peripheral blood stem cell transplantation (aPBSCT) in patients with Hodgkin lymphoma (HL) and non‐Hodgkin lymphomas (NHL). t‐MN patients treated at an earlier stage of disease evolution have a better prognosis, and this presents a need to identify patients at risk for t‐MN. Methods: Using a prospective longitudinal study design, this study evaluated peripheral blood parameters pre‐aPBSCT and on day 100, at 6 months, 1 year, 2 years, and 3 years in 304 patients treated with aPBSCT. The relation between peripheral blood parameters and subsequent development of t‐MN was examined, and nomograms were developed to identify patients at risk for t‐MN. Results: Twenty‐one patients developed t‐MN at a median of 1.95 years post‐aPBSCT. Hemoglobin, hematocrit, white blood cell, and platelet counts were lower among patients who developed t‐MN compared to those who did not; these differences appeared soon after aPBSCT, persisted, and preceded development of t‐MN. Older age at aPBSCT (hazard ratio [HR]per_year_increase = 1.08, P =.007), exposure to total body irradiation (TBI) (HR = 2.90, P =.04), and low 100‐day platelet count (HRincrease_per_unit_decline_in_PLT = 1.01, P =.002) predicted subsequent t‐MN. These parameters and primary diagnosis allowed identification of patients at high risk of t‐MN (eg, an HL patient undergoing aPBSCT at the age of 70 years with TBI and with a day 100 PLT between 100,000 and 150,000 would have a 62% probability of developing t‐MN at 6 years post‐aPBSCT). Conclusions: Abnormalities in peripheral blood parameters can identify patients at high risk for t‐MN after aPBSCT for HL or NHL, allowing opportunities to personalize close surveillance and possible disease‐modifying interventions. In this longitudinal study of patients with lymphoma treated with autologous peripheral blood stem cell transplantation, blood parameters are altered among patients who subsequently develop therapy‐related leukemia in comparison with those who do not. These differences appear soon after transplantation, persist, and precede the development of therapy‐related myeloid neoplasms. This allows the identification of those at high risk for therapy‐related leukemia and provides opportunities to personalize close surveillance and possible disease‐modifying interventions among those at highest risk. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia.
- Author
-
Aldoss, Ibrahim, Otoukesh, Salman, Zhang, Jianying, Mokhtari, Sally, Ngo, Dat, Mojtahedzadeh, Mona, Al Malki, Monzr M., Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Koller, Paul, Ball, Brian, Stewart, Forrest, Curtin, Peter, Artz, Andrew, Nakamura, Ryotaro, Marcucci, Guido, and Forman, Stephen J.
- Subjects
EXTRAMEDULLARY diseases ,LYMPHOBLASTIC leukemia ,ACUTE leukemia ,DISEASE relapse ,DISEASE progression - Abstract
Background: Blinatumomab has demonstrated encouraging activity in relapsed/refractory (r/r) and minimal residual disease–positive (MRD+) acute lymphoblastic leukemia (ALL). Extramedullary disease (EMD) relapse or relapse with CD19– disease has been observed after blinatumomab therapy in patients with r/r or MRD+ ALL. However, the pathophysiology and risk factors of treatment failure are not fully understood. Methods: This study retrospectively reviewed the outcomes of adult patients with B‐cell ALL treated with blinatumomab (n = 132) for either r/r (n = 103) or MRD+ disease (n = 29) at the authors' center (2013‐2021) and analyzed factors associated with treatment response and EMD failure. Results: The overall response rate was 64%. A lower marrow blast burden before blinatumomab (P =.049) and no history of previous EMD (P =.019) were significantly associated with a higher response. Among the patients who responded to blinatumomab, 56% underwent consolidation with allogeneic transplantation. Blinatumomab failure was observed in 89 patients; 43% of these patients (n = 38) either progressed or relapsed at extramedullary sites. A history of extramedullary involvement (53% vs 24%; P =.005) and retention of CD19 expression at the time of relapse/progression (97% vs 74%; P =.012) were associated with a higher risk for extramedullary failure. Central nervous system (CNS) failure after blinatumomab was encountered in 39% of the patients with EMD. Conclusions: A history of EMD predicted an inferior response to blinatumomab therapy with a higher risk for relapse/progression at extramedullary sites (particularly CNS). Consolidation with allogenic transplantation in patients who primarily responded to blinatumomab did not abrogate the risk of extramedullary relapse. The incorporation of extramedullary assessment and the intensification of CNS prophylaxis may help in addressing extramedullary failure. Lay Summary: Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia.A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites.Most extramedullary failure cases retain CD19 expression. Extramedullary failure is common during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. A history of extramedullary disease predicts an inferior response to blinatumomab therapy and a higher risk for relapse/progression at extramedullary sites. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. High prevalence and inferior long‐term outcomes for TP53 mutations in therapy‐related acute lymphoblastic leukemia.
- Author
-
Pourhassan, Hoda, Yang, Dongyun, Afkhami, Michelle, Pillai, Raju, Ball, Brian, Al Malki, Monzr, Salhotra, Amandeep, Ali, Haris, Artz, Andrew, Curtin, Peter, Armenian, Saro, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Pullarkat, Vinod, Nakamura, Ryotaro, and Aldoss, Ibrahim
- Published
- 2022
- Full Text
- View/download PDF
12. A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm.
- Author
-
Clark, Mary C., Lu, Rongze Olivia, Ho, Winson S., Dias, Matheus Henrique, Bernards, René, and Forman, Stephen J.
- Subjects
- *
PHOSPHOPROTEIN phosphatases , *REGULATORY T cells , *CYTOTOXIC T cells , *IMMUNE checkpoint proteins , *T cells - Abstract
Immune checkpoint blockade has emerged as a potent new tool in the war on cancer. However, only a subset of cancer patients benefit from this therapeutic modality, sparking a search for combination therapies to increase the fraction of responding patients. We argue here that inhibition of protein phosphatase 2A (PP2A) is a promising approach to increase responses to immune checkpoint blockade and other therapies that rely on the presence of tumor‐reactive T cells. Inhibition of PP2A increases neoantigen expression on tumor cells, activates the cGAS/STING pathway, suppresses regulatory T cells, and increases cytotoxic T cell activation. In preclinical models, inhibition of PP2A synergizes with immune checkpoint blockade and emerging evidence indicates that patients who have tumors with mutations in PP2A respond better to immune checkpoint blockade. Therefore, inhibition of PP2A activity may be an effective way to sensitize cancer cells to immune checkpoint blockade and cell‐based therapies using tumor‐reactive T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
- Author
-
Othman T, Koller P, Tsai NC, Yang D, Pourhassan H, Agrawal V, Ngo D, Chen J, Farol L, Spielberger R, Sahebi F, Al Malki MM, Cai JL, Sandhu KS, Mansour J, Salhotra A, Ali H, Aribi A, Arslan S, Marcucci G, Forman SJ, Stein AS, Nakamura R, Pullarkat V, Aldoss I, and Mei M
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Retrospective Studies, Aged, Maintenance Chemotherapy, Philadelphia Chromosome, Pyridazines therapeutic use, Pyridazines adverse effects, Pyridazines administration & dosage, Imatinib Mesylate therapeutic use, Imatinib Mesylate adverse effects, Imatinib Mesylate administration & dosage, Imidazoles adverse effects, Imidazoles administration & dosage, Imidazoles therapeutic use, Young Adult, Transplantation, Homologous, Adolescent, Tyrosine Kinase Inhibitors, Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage
- Abstract
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to prevent relapse is tyrosine kinase inhibitor (TKI) maintenance post-HCT, but published clinical experience is primarily with the first-generation TKI imatinib while data with newer generation TKIs are limited. We conducted a retrospective analysis of 185 Ph+ ALL patients who underwent HCT followed by TKI maintenance from 2003 to 2021 at City of Hope. Initially, 50 (27.0%) received imatinib, 118 (63.8%) received a second-generation TKI (2G-TKI), and 17 (9.2%) received ponatinib. A total of 77 patients (41.6%) required a dose reduction of their initial TKI due to toxicity. Sixty-six patients (35.7%) did not complete maintenance due to toxicity; 69 patients (37.3%) discontinued 1 TKI, and 11 (5.9%) discontinued 2 TKIs due to toxicity. Initial imatinib versus 2G-TKI versus ponatinib maintenance was discontinued in 19 (38.0%) versus 68 (57.6%) versus 3 (17.6%) patients due to toxicity (p = .003), respectively. Patients on ponatinib as their initial TKI had a longer duration of TKI maintenance versus 2G-TKI: 576.0 days (range, 72-921) versus 254.5 days (range, 3-2740; p = .02). The most common reasons for initial TKI discontinuation include gastrointestinal (GI) intolerance (15.1%), cytopenia (8.6%), and fluid retention (3.8%). The 5-year overall survival and progression-free survival for the total population were 78% and 71%, respectively. Our findings demonstrate the challenges of delivering post-HCT TKI maintenance in a large real-world cohort as toxicities leading to TKI interruptions, discontinuation, and dose reduction were common., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
14. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
- Author
-
Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, and Pullarkat V
- Subjects
- Adult, Humans, Retrospective Studies, Inotuzumab Ozogamicin therapeutic use, Remission Induction, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Hematopoietic Stem Cell Transplantation, Antibodies, Bispecific therapeutic use
- Abstract
Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is associated with a poor response to standard chemotherapy. However, outcomes with novel antibody and cellular therapies in relapsed/refractory (r/r) Ph-like ALL are largely unknown. We conducted a single-center retrospective analysis of adult patients (n = 96) with r/r B-ALL and fusions associated with Ph-like who received novel salvage therapies. Patients were treated with 149 individual novel regimens (blinatumomab = 83, inotuzumab ozogamicin [InO] = 36, and CD19CAR T cells = 30). The median age at first novel salvage therapy was 36 years (range; 18-71). Ph-like fusions were IGH::CRLF2 (n = 48), P2RY8::CRLF2 (n = 26), JAK2 (n = 9), ABL-class (n = 8), EPOR::IGH (n = 4) and ETV6::NTRK2 (n = 1). CD19CAR T cells were administered later in the course of therapy compared to blinatumomab and InO (p < .001) and more frequently in recipients who relapsed after allogeneic hematopoietic cell transplantation (alloHCT) (p = .002). Blinatumomab was administered at an older age compared to InO and CAR T-cells (p = .004). The complete remission (CR)/CR with incomplete hematologic recovery (CRi) rates were 63%, 72%, and 90% following blinatumomab, InO and CD19CAR, respectively, among which 50%, 50%, and 44% of responders underwent consolidation with alloHCT, respectively. In multivariable analysis, the type of novel therapy (p = .044) and pretreatment marrow blasts (p = .006) predicted the CR/CRi rate, while the Ph-like fusion subtype (p = .016), pretreatment marrow blasts (p = .022) and post-response consolidation with alloHCT (p < .001) influenced event-free survival. In conclusion, novel therapies are effective in inducing high remission rates in patients with r/r Ph-like ALL and successfully transitioning the responders to alloHCT., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.